3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
9
Thoracic
4
Head & Neck
4
Gynecologic
3
Breast
3
Lymphoid
2
Genitourinary
2
Sarcoma
1
Other solid neoplasm
1
NET
1
Endocrine
1
Dermatologic
1
Conditions
Sarcoma
43
Melanoma
19
Neoplasms
12
Squamous Cell Carcinoma of Head and Neck
11
Neoplasm Metastasis
11
Carcinoma, Non-Small-Cell Lung
9
Breast Neoplasms
9
Glioblastoma
8
Colorectal Neoplasms
8
Triple Negative Breast Neoplasms
7
Pancreatic Neoplasms
7
Ovarian Neoplasms
7
Gliosarcoma
7
Lung Neoplasms
6
Histiocytoma, Malignant Fibrous
6
Carcinoma, Renal Cell
6
Osteosarcoma
5
Liposarcoma
5
Head and Neck Neoplasms
5
Carcinoma, Hepatocellular
5
Uterine Cervical Neoplasms
4
Sarcoma, Synovial
4
Sarcoma, Kaposi
4
Neurofibrosarcoma
4
Lymphoma
4
Hemangiosarcoma
4
Carcinoma, Merkel Cell
4
Urinary Bladder Neoplasms
3
Stomach Neoplasms
3
Recurrence
3
Interventions
Oxaliplatin
2
Observation
2
Leucovorin
2
Irinotecan
2
Ipilimumab
2
Cisplatin
2
tivozanib
1
spartalizumab
1
seribantumab
1
pembrolizumab
1
motexafin lutetium
1
entinostat
1
atezolizumab
1
Thalidomide
1
Specimen Handling
1
Quality of Life
1
Pharmacogenomic Testing
1
Peripheral Blood Stem Cell Transplantation
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Octreotide
1
Nivolumab
1
Molecular Diagnostic Techniques
1
Mesna
1
Magnetic Resonance Spectroscopy
1
Immunotherapy
1
Ifosfamide
1
Fluorouracil
1
Floxuridine
1
Filgrastim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Bile Duct Neoplasms
×
pembrolizumab
×
Sarcoma
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts